Breaking News Instant updates and real-time market news.

ORCL

Oracle

$48.75

-4.04 (-7.65%)

, EFX

Equifax

$92.93

-3.735 (-3.86%)

16:15
09/15/17
09/15
16:15
09/15/17
16:15

On The Fly: Top stock stories for Friday

Stocks opened mixed but before long all three of the major equity averages were in positive territory. The early weakness followed the report of another missile firing by North Korea, a terrorist bombing in London, and weaker than expected data on retail sales and industrial production in the U.S. The averages hung onto their gains, capping a winning weak. Meanwhile, oil prices drifted for most of the day and closed a few pennies shy of the $50 dollar a barrel level. ECONOMIC EVENTS: In the U.S., industrial production fell 0.9% with capacity utilization at 76.1% in August. Those are weaker than expected, but the Fed said Hurricane Harvey reduced IP by about 0.75%. retail sales fell 0.2% in August, with the ex-auto component up 0.2%. Retail sales fell 0.2% in August, versus expectations for them to have risen 0.1%. Excluding cars, sales rose 0.2%, which was less than the 0.5% consensus forecast. The Empire State manufacturing survey headline reading fell slightly in September to 24.4 from a 3-year high of 25.2 in August. The University of Michigan said its consumer-sentiment index dropped to 95.3 in its preliminary September reading, down from the final August reading of 96.8. In energy news, Baker Hughes reported that the U.S. rig count is down 8 rigs from last week to 936. COMPANY NEWS: Shares of Oracle (ORCL) slipped 7.8% after the company reported quarterly results that were widely called "solid" by analysts, but issued constant currency guidance for the new quarter that missed estimates... Meanwhile, Equifax (EFX) has continued to experience mounting troubles associated with the massive data breach it disclosed last week. The company's European division today said that about 400,000 European customers have been hacked as well, while in the U.S. a group of Attorneys General issued a letter to Equifax's attorney requesting that the company stop selling credit monitoring services until the sign-up period for the free credit monitoring service has ended. Shares of Equifax continued their slide, falling an additional 3.74% today. MAJOR MOVERS: Among the noteworthy gainers was Abeona Therapeutics (ABEO), which surged 22.86% higher after the stock was initiated with an Outperform rating at RBC Capital. Also higher was Resolute Energy (REN), which gained 9.2% after it agreed to sell its subsidiary that holds interest in Aneth Field to an affiliate of Elk Petroleum for a total potential consideration of $195M. Among the notable losers was BioTelemetry (BEAT), which fell 11.86% after Off Wall Street initiated coverage of the stock with a Sell rating and $21 price target. Also lower was Acuity Brands (AYI), which slid 4.2% after an analyst from Wells Fargo downgraded the stock to Market Perform from Outperform. INDEXES: The Dow rose 64.86, or 0.29%, to 22,268.34, the Nasdaq gained 19.38, or 0.3%, to 6,448.47, and the S&P 500 advanced 4.61, or 0.18%, to 2,500.23.

ORCL

Oracle

$48.75

-4.04 (-7.65%)

EFX

Equifax

$92.93

-3.735 (-3.86%)

ABEO

Abeona Therapeutics

$17.20

3.2 (22.86%)

REN

Resolute Energy

$30.08

2.505 (9.09%)

BEAT

BioTelemetry

$32.70

-4.4 (-11.86%)

AYI

Acuity Brands

$170.55

-7.44 (-4.18%)

  • 19

    Sep

  • 25

    Sep

ORCL Oracle
$48.75

-4.04 (-7.65%)

09/15/17
MUFG
09/15/17
NO CHANGE
Target $61
MUFG
Overweight
Oracle should be bought on post-earnings weakness, says MUFG
MUFG analyst Stephen Bersey earlier today lowered his price target for Oracle shares to $61 from $63 but reiterated an Overweight rating on the name. The company last night posted a "solid" quarter as it continues its transition to the cloud, Bersey told investors in a research note. Oracle sustained 50%-plus year-over-year cloud revenue growth rates even as cloud revenue passed $1B in Q2 of FY17, Bersey noted. He recommends building or adding to positions on the post-earnings share weakness.
09/15/17
ADAM
09/15/17
NO CHANGE
Target $57
ADAM
Buy
Oracle key metrics better than expected, says Canaccord
Canaccord analyst Richard Davis said Oracle posted its third consecutive positive quarterly surprise, with most of the key metrics at least a little better than expected. He said his view remains unchanged and that the stock will outperform in down or choppy markets. Davis reiterated his Buy rating and raised his price target to $57 from $56 on Oracle shares.
09/15/17
UBSW
09/15/17
NO CHANGE
Target $57
UBSW
Buy
Oracle price target raised to $57 from $52 at UBS
UBS analyst Fatima Boolani raised her price target on Oracle to $57 from $52 following good Q1 results in what is normally a slow quarter. The analyst noted Q2 has tougher comps, causing the guidance to be somewhat mixed. Boolani reiterated her Buy rating on Oracle shares.
09/15/17
JMPS
09/15/17
NO CHANGE
JMPS
Market Perform
JMP says Oracle Q2 guidance suggests prior cloud assumptions too optimistic
JMP Securities analyst Patrick Walravens said Oracle reported "solid" Q1 results, but he blames the afterhours slide in the stock to high expectations coming into the call and constant currency guidance that missed estimates. The analyst, who said the Q2 guidance suggests that his prior cloud growth assumptions were too optimistic, keeps a Market Perform rating on Oracle shares, which are down over 4% to $50.55 in pre-market trading.
EFX Equifax
$92.93

-3.735 (-3.86%)

09/15/17
BARD
09/15/17
NO CHANGE
Target $115
BARD
Outperform
Equifax price target lowered to $115 from $141 at Baird
Baird analyst Jeffrey Mueler lowered his price target on Equifax to $115 from $141 as he reduced his Global Consumer revenue estimate while assuming tougher U.S. B2B new sales and cross-sales and some volume share loss. He is also assuming increased expenses and removing share repurchases from his estimates. Mueler maintained his Outperform rating on Equifax shares.
09/15/17
09/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Equifax (EFX) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing news of a major hack on the company's data that could have lasting effects. 2. FedEx (FDX) downgraded to Neutral from Buy at UBS with analyst Thomas Wadewitz citing TNT issues following the cyber-attack in June that knocked out multiple systems. 3. Carnival (CCL) downgraded to Neutral from Outperform at Credit Suisse with analyst Tim Ramskil saying he is worried that his estimate of absolute industry capacity growth in 2018-2021 is double that of the last five years. 4. American Airlines (AAL), United Continental (UAL), and Spirit Airlines (SAVE) were downgraded to Neutral from Overweight at JPMorgan. 5. Acuity Brands (AYI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Richard Kwas saying his firm's electrical channel checks indicate the 8% consensus organic revenue growth estimate for FY18 does not have upside. The analyst thinks shares are likely range-bound in the $160-$200 range "for the time being." He believes a "material step up" in tiered solutions growth is needed for gross margin to outperform expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/17
09/15/17
NO CHANGE

SunTrust lowers Equifax, TransUnion price targets but advises buying stocks
SunTrust analyst Andrew Jeffrey cut his price target on Equifax (EFX) to $110 from $155 and lowered his price target on TransUnion (TRU) to $48 from $54. As reasons for the reductions, he cited increased competition from free credit monitoring programs and the risk of share loss in the wake of the Equifax data breach. However, he believes that both stocks reflect an "overstated" risk of negative legislative and/or regulatory changes. Jeffrey does not expect governments to create "barriers to complete and comprehensive data access," since, according to the analyst, lenders and many service providers rely on the data generated by the credit bureaus. He recommends buying both stocks.
09/15/17
ARGS
09/15/17
DOWNGRADE
ARGS
Hold
Equifax downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Equifax to Hold following news of a major hack on the company's data that could have lasting effects. Hellweg does not believe the company has handled the aftermath of the breach very well and notes more than two dozen class-action lawsuits have been filed against Equifax and members of Congress have called for additional regulation of the credit reporting industry.
ABEO Abeona Therapeutics
$17.20

3.2 (22.86%)

03/06/17
FBRC
03/06/17
NO CHANGE
FBRC
FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
07/19/17
MAXM
07/19/17
NO CHANGE
Target $17
MAXM
Buy
Abeona Therapeutics price target raised to $17 from $14 at Maxim
Maxim analyst Jason McCarthy noted that Abeona Therapeutics announced FDA guidance for accelerating EB-101 into a Phase 3 pivotal program in epidermolysis bullosa and that the gene therapy corrected skin grafts have demonstrated proof of concept data in the early going of a Phase 1/2 study in Recessive Dystrophic Epidermolysis Bullosa patients. Factoring in the potential for a RDEB indication for EB-101, McCarthy raised his price target on Abeona to $17 from $14 and keeps a Buy rating on the stock.
09/14/17
RBCM
09/14/17
INITIATION
Target $23
RBCM
Outperform
Abeona Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler started Abeona Therapeutics with an Outperform rating and $23 price target.
01/06/17
JEFF
01/06/17
INITIATION
Target $11
JEFF
Buy
Abeona Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Gena Wang started Abeona Therapeutics with a Buy rating and $11 price target. The analyst sees a favorable risk/reward ahead of data readouts in the first half of 2017.
REN Resolute Energy
$30.08

2.505 (9.09%)

09/15/17
KLRG
09/15/17
NO CHANGE
KLRG
Resolute Energy price target raised to $64 from $60 at KLR Group
KLR Group analyst John Gerdes maintained his Buy rating and raised his price target on Resolute Energy to $64 from $60, based on the company's accretive divestiture of its non-core Aneth field in the Paradox Basin of southeast Utah.
07/18/17
IMPC
07/18/17
INITIATION
Target $40
IMPC
Outperform
Resolute Energy initiated with an Outperform at Imperial Capital
Imperial Capital analyst Jason Wangler started Resolute Energy with an Outperform rating and $40 price target.
07/17/17
GSCO
07/17/17
INITIATION
Target $32
GSCO
Neutral
Resolute Energy initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Jon Nelson started Resolute Energy with a Neutral rating and $32 price target. The analyst believes the bull case for shares is being constrained by funding uncertainty.
06/01/17
06/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pentair (PNR) reinstated with a Sell at Goldman Sachs. 2. Global Payments (GPN) coverage resumed with a Buy at Stifel. 3. Caesars (CZR) initiated with an Outperform at Oppenheimer. 4. Resolute Energy (REN) initiated with a Buy at SunTrust. 5. Ziopharm (ZIOP) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BEAT BioTelemetry
$32.70

-4.4 (-11.86%)

07/14/17
LSCM
07/14/17
NO CHANGE
Target $50
LSCM
Buy
BioTelemetry price target raised to $50 from $35 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for BioTelemetry to $50 saying the recently closed LifeWatch acquisition should drive profitable growth and position the arrhythmia monitoring platform for expansion. The analyst believes investors should buy the stock now, before the Q2 results. He reiterates a Buy rating on the name.
12/02/16
DOTC
12/02/16
INITIATION
Target $26
DOTC
Buy
BioTelemetry initiated with a Buy at Dougherty
Dougherty analyst Gene Mannheimer initiated BioTelemetry with a Buy and a $26 price target.
09/15/17
BNCH
09/15/17
NO CHANGE
Target $44
BNCH
Buy
Benchmark says BioTelemetry has big head start over iRhythm
Following Off Wall Street's Sell rating on BioTelemetry, Benchmark analyst Bill Sutherland says recent discussions with management has raised no "red flags" about the outlook for the company's legacy business. In an email to investors, the analyst notes that BioTelemetry has a large head start over competitor iRhythm (IRTC), which Off Wall Street references in its short report. He adds that the holter monitor segment, while large, is not BioTelemetry's focus. Sutherland has a Buy rating on the shares with a $44 price target. BioTelemetry is down 11%, or $4.15, to $32.95 in afternoon trading.
AYI Acuity Brands
$170.55

-7.44 (-4.18%)

09/15/17
WELS
09/15/17
DOWNGRADE
WELS
Market Perform
Acuity Brands downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Richard Kwas downgraded Acuity Brands to Market Perform saying his firm's electrical channel checks indicate the 8% consensus organic revenue growth estimate for FY18 does not have upside. The analyst thinks shares are likely range-bound in the $160-$200 range "for the time being." He believes a "material step up" in tiered solutions growth is needed for gross margin to outperform expectations.
09/14/17
WELS
09/14/17
DOWNGRADE
WELS
Market Perform
Acuity Brands downgraded to Market Perform from Outperform at Wells Fargo
06/06/17
WELS
06/06/17
NO CHANGE
Target $200
WELS
Outperform
Acuity Brands rises after Wells Fargo signals better demand
Shares of Acuity Brands are rising in early trading after Wells Fargo analyst Richard Kwas reported in a pre-open note to investors that the firm's channel checks revealed that agents and distributors are seeing better year-over-year growth in the second quarter than they did in the first three months of the year. Ahead of the company's earnings report on June 29, Kwas contends that the consensus revenue forecast "looks beatable" and he raised his price target on Acuity to $200 from $196. Kwas maintains an Outperform rating on the stock, which is up $3.85, or 2.3%, to $172.01 in morning trading.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.